IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis.

ABSTRACT:

Background

In subjects with psoriasis, inflammation and epidermal hyperplasia are thought to be controlled by T cell-derived cytokines. Evidence suggests that the T(H)17 cell cytokine IL-17A (IL-17) might play a role in disease pathogenesis.

Objective

We sought to understand the effect that neutralization of IL-17 has on the clinical features of psoriasis and to understand the role that IL-17 has in inflammatory pathways underlying psoriasis in human subjects.

Methods

We examined skin lesions obtained from 40 subjects participating in a phase I, randomized, double-blind, placebo-controlled trial of the anti-IL-17 mAb ixekizumab (previously LY2439821) in which subjects received 5, 15, 50, or 150 mg of subcutaneous ixekizumab or placebo at weeks 0, 2, and 4.

Results<

SUBMITTER: Krueger JG 

PROVIDER: S-EPMC3470466 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature